Skymab chaired the Clinical GPCR session and participated in expert roundtable discussions focused on emerging GPCR-targeted therapeutic modalities, including ADCs and radioconjugates.
The meeting provided an opportunity to exchange with international experts and pharmaceutical partners advancing precision oncology.